Eric Roeland, MD, of the University of California, San Diego, and Timothy E. Quill, MD, of the University of Rochester Medical Center, discuss the debate on whether physician-assisted death should be a legally available option at the end of life when neither palliative nor hospice care is satisfactory.
Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506). To see the French language version of this discussion, click here.
Nikhil Wagle, MD, of the Dana-Farber Cancer Institute, discusses the strides made in this national direct-to-patient initiative to accelerate genomics research (Abstract LBA1519).
Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advanced/metastatic disease (Abstract LBA4500).
Eric Roeland, MD, of the University of California, San Diego, and Linda Van Le, MD, of the University of North Carolina discuss ways to manage symptoms that affect up to 80% of postmenopausal women, diminishing their quality of life.
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in patients with epithelial ovarian cancer (Abstract LBA5503).
